
Your Feed
Can Resistance Exercise Help Heal Bone Lesions in Multiple Myeloma? | IMS 2026
Can CD4/CD8 T-Cell Ratio Predict Parkinson-Like Side Effects After BCMA CAR-T in Myeloma | IMS 2026
Can Iberdomide Replace Revlimid in Newly Diagnosed Myeloma? KId Results | IMS 2026
MajesTEC-3: Could Teclistamab + Daratumumab Lead to a “Functional Cure” in Myeloma? | IMS 2026
Infection Prevention in Multiple Myeloma: What Patients Need to Know | IMS 2026
MajesTEC-5: High MRD-Negative Rates With Talquetamab Combo in Newly Diagnosed Myeloma | IMS 2026
Top 5 Things Newly Diagnosed Multiple Myeloma Patients Should Know | IMS 2026
CARTITUDE-2: Can Earlier Cilta-Cel CAR-T Lead to Long-Term Remission or Cure in Myeloma? | IMS 2026
ENDURANCE Trial: Can Myeloma Patients Stop Revlimid Maintenance After 2 Years? | IMS 2026
Iberdomide Plus Dara After Transplant: Early Safety and Results | IMS 2026
Multiple Myeloma Side Effects: When Should You Call Your Care Team? | IMS 2026
Second Cancers After Myeloma: Who Faces Higher Risk? | IMS 2026
How Is Myeloma Treatment Changing? Quadruplets, CAR-T, Bispecifics and New Therapies | IMS 2026
Personalized Vaccine for Smoldering Myeloma: Could It Prevent Progression? | IMS 2026
Should You Use the Best Myeloma Treatments Early or Save Them for Relapse?
Talquetamab Taste Changes in Multiple Myeloma: What Helps and What Doesn’t? -TALISMAN Study | #IMS26
Transplant-Ineligible Myeloma: Can Daratumumab + Bortezomib Maintenance Improve Outcomes? | #IMS26




